

AMENDMENTS TO THE CLAIMS

1. (Original) A crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having a diffraction peak at a diffraction angle ( $2\theta \pm 0.2^\circ$ ) of  $11.4^\circ$  in a powder X-ray diffraction.
2. (Original) A crystalline form (Form C) according to claim 1 further having a diffraction peak at a diffraction angle ( $2\theta \pm 0.2^\circ$ ) of  $19.1^\circ$  in a powder X-ray diffraction.
3. (Original) A crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having an absorption peak at a wavenumber of  $1410 \pm 1 \text{ cm}^{-1}$  in an infrared absorption spectrum (KBr).
4. (Original) A crystalline form (Form C) according to claim 3 further having an absorption peak at a wavenumber of  $1443 \pm 1 \text{ cm}^{-1}$  in an infrared absorption spectrum (KBr).
5. (Original) A crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide having a peak at a chemical shift of approximately 143.4 ppm in a  $^{13}\text{C}$  solid state NMR spectrum.
6. (Original) A crystalline form (Form C) according to claim 5 further having a peak at a chemical shift of approximately 131.1 ppm in a  $^{13}\text{C}$  solid state NMR spectrum.
7. (Currently amended) A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to ~~any one of claims 1 to 6~~ claim 1, characterized in that N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is crystallized using a simple solvent selected from the group consisting of n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, s-butyl alcohol, t-butyl alcohol and water, or a mixed solvent thereof as a crystallization solvent.

8. (Original) A process according to claim 7, wherein the crystallization solvent is a simple solvent of isopropyl alcohol or s-butyl alcohol, or a mixed solvent of s-butyl alcohol and water or a mixed solvent of isopropyl alcohol and water.

9. (Original) A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3:1-5:1) or a mixed solvent of isopropyl alcohol and water (volume ratio = 9:1-10:1).

10. (Original) A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3.9:1-4.1:1).

11. (Original) A process according to claim 7, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized.

12. (Original) A process according to claim 7, wherein N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and dissolved in a solvent and then crystallized by gradual cooling.

13. (Currently amended) A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to ~~any one of claims 1 to 6~~ claim 1, characterized in that N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated at 80-130°C.

14. (Currently amended) A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to ~~any one of claims 1 to 6~~ claim 1, characterized in that N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide is heated and stirred in water at 60-90°C.

15. (Currently amended) A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to ~~any one of claims 1 to 6~~ claim 1, characterized in that a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate are heated at 80-130°C.

16. (Currently amended) A process for preparing a crystalline form (Form C) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide according to ~~any one of claims 1 to 6~~ claim 1, characterized in that a crystalline form of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate are heated and stirred in water at 60-90°C.

17. (Original) A crystalline form (Form A) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate having a diffraction peak at a diffraction angle ( $2\theta \pm 0.2^\circ$ ) of  $8.5^\circ$  in a powder X-ray diffraction.

18. (Original) A crystalline form (Form A) according to claim 17 further having a diffraction peak at a diffraction angle ( $2\theta \pm 0.2^\circ$ ) of  $25.8^\circ$  in a powder X-ray diffraction.

19. (Original) A crystalline form (Form A) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate having an absorption peak at a wavenumber of  $616 \pm 1 \text{ cm}^{-1}$  in an infrared absorption spectrum (KBr).

20. (Original) A crystalline form (Form A) according to claim 19 further having an absorption peak at a wavenumber of  $802 \pm 1 \text{ cm}^{-1}$  in an infrared absorption spectrum (KBr).

21. (Original) A crystalline form (Form A) of N-(3-cyano-4-methyl-1*H*-indol-7-yl)-3-cyanobenzenesulfonamide hydrate having a peak at a chemical shift of approximately 134.7 ppm in a  $^{13}\text{C}$  solid state NMR spectrum.

22. (Original) A crystalline form (Form A) according to claim 21 further having a peak at a chemical shift of approximately 126.3 ppm in a  $^{13}\text{C}$  solid state NMR spectrum.